MX342176B - Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. - Google Patents

Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.

Info

Publication number
MX342176B
MX342176B MX2014003801A MX2014003801A MX342176B MX 342176 B MX342176 B MX 342176B MX 2014003801 A MX2014003801 A MX 2014003801A MX 2014003801 A MX2014003801 A MX 2014003801A MX 342176 B MX342176 B MX 342176B
Authority
MX
Mexico
Prior art keywords
viral disease
amelioration
pyrimidin
prevention
derivatives
Prior art date
Application number
MX2014003801A
Other languages
English (en)
Other versions
MX2014003801A (es
Inventor
So Sung-Sau
Wolkerstorfer Andrea
Szolar Oliver
Cusack Stephen
Langer Thierry
Giethlen Bruno
Morice Christophe
Michautsimon Céline
Jung Laurence
Classen-Houben Dirk
Smith Mark
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014003801A publication Critical patent/MX2014003801A/es
Publication of MX342176B publication Critical patent/MX342176B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un compuesto que tiene la fórmula general (II), opcionalmente en la forma de una sal, solvato, polimorfo, profármaco, tautómero, racemato, enantiómero, o diastereómero o una mezcla de los mismos, farmacéuticamente aceptables, que es útil en el tratamiento, mejora o prevención de una enfermedad viral. Además se describen terapias combinadas específicas.
MX2014003801A 2011-10-21 2012-10-19 Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. MX342176B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161550057P 2011-10-21 2011-10-21
PCT/EP2012/070760 WO2013057253A1 (en) 2011-10-21 2012-10-19 Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (2)

Publication Number Publication Date
MX2014003801A MX2014003801A (es) 2015-03-11
MX342176B true MX342176B (es) 2016-09-20

Family

ID=47189887

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003801A MX342176B (es) 2011-10-21 2012-10-19 Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.

Country Status (12)

Country Link
US (2) US20130102601A1 (es)
EP (1) EP2794616B1 (es)
JP (1) JP6033873B2 (es)
KR (1) KR20140097197A (es)
CN (1) CN103958521B (es)
BR (1) BR112014008412A2 (es)
CA (1) CA2852843A1 (es)
ES (1) ES2589459T3 (es)
HK (1) HK1199881A1 (es)
MX (1) MX342176B (es)
RU (1) RU2014120477A (es)
WO (1) WO2013057253A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074880A (zh) 2014-07-07 2017-08-18 萨维拉制药有限公司 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途
JP2017525777A (ja) * 2014-08-28 2017-09-07 エックス−ケム，インコーポレーテッド 可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用
WO2016133888A1 (en) * 2015-02-16 2016-08-25 Biota Pharmaceuticals, Inc. Compounds for treating respiratory syncytial virus infections
CA2984130C (en) 2015-04-28 2021-07-20 Shionogi & Co., Ltd. Substituted polycyclic pyridone derivative and prodrug thereof
US20170081331A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
SG11201804348SA (en) * 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
WO2018001948A1 (en) 2016-06-29 2018-01-04 F. Hoffmann-La Roche Ag Pyridazinone-based broad spectrum anti-influenza inhibitors
CN110494141A (zh) 2016-08-10 2019-11-22 盐野义制药株式会社 含有被取代的多环性吡啶酮衍生物及其前药的药物组合物
CN111032646B (zh) 2017-08-01 2023-01-03 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的吡唑并和三唑并双环化合物
US10851102B2 (en) 2019-01-23 2020-12-01 Theravance Biopharma R&D Ip, Llc Imidazole and triazole containing bicyclic compounds as JAK inhibitors
US11932656B1 (en) 2023-10-06 2024-03-19 King Faisal University Thieno[2,3-d]pyrimidines as COX-2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
KR100714519B1 (ko) * 2002-03-07 2007-05-07 에프. 호프만-라 로슈 아게 이환 피리딘 및 피리미딘 ｐ38 키나아제 억제제
EP1790638B1 (en) 2004-09-15 2013-04-03 Shionogi Co., Ltd. Carbamoylpyridone derivative having hiv integrase inhibitory activity
CA2703600C (en) * 2007-11-15 2017-04-25 Ym Biosciences Australia Pty Ltd Fused thieno or pyrrolo pyrimidine heterocyclic compounds and use thereof as jak1, jak2, and/or jak3 inhibitors
EP2923734B1 (en) 2009-03-13 2018-01-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Purine analogues and their use as immunosuppressive agents
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
US8835461B2 (en) 2009-03-26 2014-09-16 Shionogi & Co., Ltd. Substituted 3-hydroxy-4-pyridone derivative
WO2011000566A2 (en) * 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections

Also Published As

Publication number Publication date
KR20140097197A (ko) 2014-08-06
HK1199881A1 (en) 2015-07-24
MX2014003801A (es) 2015-03-11
BR112014008412A2 (pt) 2017-04-11
ES2589459T3 (es) 2016-11-14
JP6033873B2 (ja) 2016-11-30
US20130102601A1 (en) 2013-04-25
CN103958521B (zh) 2016-10-19
EP2794616A1 (en) 2014-10-29
CN103958521A (zh) 2014-07-30
EP2794616B1 (en) 2016-06-29
CA2852843A1 (en) 2013-04-25
WO2013057253A1 (en) 2013-04-25
JP2014530838A (ja) 2014-11-20
RU2014120477A (ru) 2015-11-27
US20160376286A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
MX2014014106A (es) Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral.
MX2014003801A (es) Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
MX2014014109A (es) Derivados de 7-oxo-4,7-dihidro-pirazolo[1,5-a]pirimidina que son utiles en el tratamiento, mejora o prevencion de una enfermedad viral.
MX2014003803A (es) Derivados de acido heteroarilo hidroxamico y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
MX2015008288A (es) Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
MX349159B (es) Derivados deuterados de ivacaftor.
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
IN2014KN00948A (es)
EA201391319A1 (ru) Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
MY183582A (en) Deuterated cftr potentiators
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MX2013011591A (es) Métodos y composiciones para tratar enfermedades neurodegenerativas.
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MY183398A (en) Derivatives of azaindazole or diazaindazole type for treating pain
MX2013012588A (es) Inhibidores de cinasa.
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
IN2015MN00002A (es)
WO2013177349A3 (en) Quinazolinediones as tankyrase inhibitors
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX2015008292A (es) Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
PH12014502747A1 (en) Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Legal Events

Date Code Title Description
FG Grant or registration